No­vo Nordisk’s once-a-day sick­le cell dis­ease drug etavopi­vat cut the rate of pain crises in a year­long mid-stage study.

In the phase 3 Essence trial, a once-weekly dose of semaglutide 2.4 mg helped to improve liver fibrosis with no worsening of steatohepatitis and to resolve steatohepatitis with no worsening of ...